Obligation to Exploit. Company shall use commercially reasonable efforts to bring one or more Licensed Products to market and to meet the market demand therefor.
Obligation to Exploit. Licensee shall [*] bring Licensed Products to market and to meet the market demand therefor.
Obligation to Exploit. Licensee shall use commercially reasonable efforts to bring one or more Licensed Products to market and to meet the market demand therefor. Beginning November 30, 1995 and semi-annually thereafter, Licensee shall deliver to The Regents a progress report covering Licensee's activities related to the development and testing of Licensed Products and the obtaining of any applicable governmental approvals necessary for marketing Licensed Products. Licensee shall make these progress reports until the first commercial sale of a Licensed Product occurs anywhere in the world. Progress reports submitted by Licensee pursuant to this Section 12.1 shall include, but not be limited to, the following topics: (a) summary of work completed, (b) summary of work in progress, (c) current schedule of anticipated milestones, and (d) market plans for introduction of Licensed Products, and (e) number of full-time equivalent (FTEs) employees or agents working on the development of Licensed Products.
Obligation to Exploit. If after January 1, 1994, AVI and AVI Affiliates together effectively cease development of Products based on the Technology, as evidenced by AVI, AVI Affiliates, and/or their successors and assigns in the aggregate having for a period of more than 180 consecutive days less than the equivalent of ten (10) full time employees devoted to development, testing, commercialization, production and/or sales of one or more products based on the Technology, then, upon request by AGD, AVI will grant to AGD an exclusive royalty-free license, with right to sublicense, to make, have made, use, sell, or otherwise distribute the Products, to practice the Technology, and to use the Trademarks.
Obligation to Exploit. 23 9.2 Milestones ................................................ 23 9.3 Remedy .................................................... 24 9.4 Adjustment ................................................ 24 ARTICLE 10 - GENERAL ..................................................... 24
Obligation to Exploit. Pegas shall use commercially reasonable efforts to bring one or more Patented Products and/or Other Royalty Products to market and to meet the market demand therefor.
Obligation to Exploit. 13.00 Sale of the Licensed Products is based on a variety of factors, many of which are not in the Licensee’s control. Licensee only guarantees that it will use its best efforts to promote and sell the Licensed Products. Licensor understands that Licensee makes no other guarantees and/or representations related to the sale of the Licensed Products.
13.01 Licensor realizes that Licensee may sell a large variety of products, some of which may directly, or indirectly, compete with the Licensed Products. Licensor acknowledges that Licensee may now or in the future develop or acquire such competing products.
Obligation to Exploit. DAS shall use commercially reasonable efforts to bring Control Release Buprenorphine to market and to meet the market demand therefor.
Obligation to Exploit. Notwithstanding anything to the contrary contained in Section 6(b) above, the Purchaser shall use reasonable commercial efforts to bring at least one (1) Product to market as timely and efficiently as commercially reasonable through industry accepted preclinical and clinical development, including but not limited to research and development, manufacturing, laboratory and clinical testing and marketing. If such Product is ultimately accepted by the FDA, the Purchaser agrees to use reasonable commercial efforts to exploit such Product to the fullest extent; provided, however, that the Purchaser shall not be required to continue to exploit the Technology (including, but not limited to bringing a Product to market) if, in the reasonable judgment of the Purchaser, (a) the potential financial benefits from such exploitation would not justify the costs associated therewith or (b) at any time, a preclinical or clinical trial fails to demonstrate a safe or effective compound.
Obligation to Exploit. DAS shall use commercially reasonable efforts to bring Control Release Naltrexone to market and to meet the market demand therefor.
